ホーム › トリプルネガティブ乳がん › ミシガン州
ミシガン州におけるトリプルネガティブ乳がんの臨床試験
ミシガン州内の拠点で、トリプルネガティブ乳がんに関する28件の研究が参加者を募集しています。
ミシガン州内の都市
公式研究テキスト（英語）
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- BAMF Health, Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07189871First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- Karmanos Cancer Institute, Detroit
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06799065Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- University of Michigan ( Site 0103), Ann Arbor
- Henry Ford Health ( Site 0010), Detroit
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Cancer & Hematology Centers of Western Michigan ( Site 0026), Grand Rapids
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06841354A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- BAMF Health, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07020117Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
- START Midwest, Grand Rapids
被験者募集中第1相
18歳以上 · 女性 · 2026/09/10更新 · NCT07652242Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Cancer and Hematology Centers of Western Michigan, Grand Rapids
- William Beaumont Hospital, Royal Oak
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05633654A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06400472Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Trinity Health, Ann Arbor
被験者募集中観察研究
18歳〜99歳 · 全性別 · 2026/09/03更新 · NCT07211178A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07029399A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT07115043Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/13更新 · NCT05985655A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Henry Ford Cancer- Detroit (Brigitte Harris Cancer Pavilion), Detroit
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06926868Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Karmanos Cancer Institute, Detroit
- START Midwest, Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- BAMF Health, Grand Rapids
被験者募集中第1相
18歳〜100歳 · 全性別 · 2026/07/29更新 · NCT06562192A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- START Midwest, LLC, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT07318805A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
- Karmanos Cancer Institute, Farmington Hills
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT05208762A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Henry Ford Health Hospital, Detroit
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/29更新 · NCT05377996Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- START Midwest /ID# 248685, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/23更新 · NCT05005403A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Karmanos Cancer Institute, Detroit
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/18更新 · NCT07503808BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- University of Michigan, Ann Arbor
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/15更新 · NCT05768932I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Herbert-Herman Cancer Center, Sparrow Hospital, Lansing
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/06更新 · NCT01042379JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
- Henry Ford Health System, Detroit
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/01/09更新 · NCT05490472A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- University of Michigan, Ann Arbor
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/11/04更新 · NCT05902988A Beta-only IL-2 ImmunoTherapY Study
- Karmanos Cancer Institute, Detroit
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/07/09更新 · NCT05086692CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Trinity Health-Michigan, Ypsilanti
被験者募集中観察研究
18歳以上 · 女性 · 2025/01/07更新 · NCT06230185ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。